Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 181 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: LDL Cholesterol Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stop Atherosclerosis in Native Diabetics Study

NCT00147251
View directory record Official record
Conditions
Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes, Carotid Atherosclerosis
Interventions
FDA approved drugs to treat blood pressure and cholesterol
Drug
Lead sponsor
Cynthia West
Other
Eligibility
40 Years and older
Enrollment
548 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chinle, Arizona • Phoenix, Arizona • Lawton, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Jun 11, 2026, 2:12 AM EDT
Active, not recruiting No phase listed Observational

Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice

NCT07615166
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Alirocumab 150 mg, Inclisiran
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 11, 2026, 2:12 AM EDT
Recruiting Phase 4 Interventional

DESIFOR-EXPAND (MHIF)

NCT06804980
View directory record Official record
Conditions
Statin Therapy, Statin Adverse Reaction, Statin
Interventions
Rosuvastatin (Crestor), Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Supplements, Placebo, or Rosuvastatin Study

NCT04846231
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 75 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jun 11, 2026, 2:12 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

NCT00311987
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
3,5-Diiodothyropropionic acid (DITPA) therapy
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Jun 11, 2026, 2:12 AM EDT
Completed No phase listed Observational

Patient and Provider Assessment of Lipid Management Registry

NCT02341664
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Not applicable Interventional

The Effect of Avocado on Cardiovascular Disease (CVD) Risk Factors

NCT01235832
View directory record Official record
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Avocado Diet, Lower-Fat Diet, Moderate Fat Diet
Other
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

NCT00280995
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
ISIS 301012
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

NCT00028301
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Lopinavir/Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Jun 11, 2026, 2:12 AM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

NCT04798430
View directory record Official record
Conditions
Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
10 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Evanston, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

NCT01959971
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

NCT01475825
View directory record Official record
Conditions
Hypercholesterolemia, Heterozygous Familial
Interventions
mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
20
States / cities
Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jun 11, 2026, 2:12 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Quercetin on Metabolic Health

NCT05297032
View directory record Official record
Conditions
Quercetin, Lipid Metabolism, Aging
Interventions
Quercetin Phytosome
Dietary Supplement
Lead sponsor
Thorne HealthTech, Inc
Industry
Eligibility
20 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Summerville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Obicetrapib in Combination With Ezetimibe

NCT04770389
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions
Obicetrapib 5mg, Ezetimibe 10mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Lincoln, California • Evanston, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

NCT03337308
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos
Combination Product · Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Healthy Participants With High Cholesterol

NCT01671085
View directory record Official record
Conditions
Healthy Volunteers, Hypercholesterolemia
Interventions
LY3015014, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

NCT01849497
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab Pre-filled Syringe, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
21
States / cities
Encino, California • Thousand Oaks, California • Ventura, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Jun 11, 2026, 2:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis

NCT01105715
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Not applicable Interventional Results available

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

NCT00762229
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Ezetimibe 10 mg, Ezetimibe 5 mg
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Jun 11, 2026, 2:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)

NCT01222182
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
atorvastatin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Jun 11, 2026, 2:12 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Jun 11, 2026, 2:12 AM EDT